South Korea · Delayed Price · Currency is KRW Theragen Etex Statistics
Total Valuation
Theragen Etex has a market cap or net worth of KRW 92.99 billion. The enterprise value is 116.18 billion.
| Market Cap | 92.99B |
| Enterprise Value | 116.18B |
Important Dates
The last earnings date was Thursday, April 2, 2026.
| Earnings Date | Apr 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Theragen Etex has 36.68 million shares outstanding. The number of shares has increased by 14.95% in one year.
| Current Share Class | 36.68M |
| Shares Outstanding | 36.68M |
| Shares Change (YoY) | +14.95% |
| Shares Change (QoQ) | +14.99% |
| Owned by Insiders (%) | 27.45% |
| Owned by Institutions (%) | 0.86% |
| Float | 24.11M |
Valuation Ratios
The trailing PE ratio is 9.76.
| PE Ratio | 9.76 |
| Forward PE | n/a |
| PS Ratio | 0.34 |
| PB Ratio | 0.61 |
| P/TBV Ratio | 0.74 |
| P/FCF Ratio | 11.60 |
| P/OCF Ratio | 8.66 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.28, with an EV/FCF ratio of 14.49.
| EV / Earnings | 11.94 |
| EV / Sales | 0.43 |
| EV / EBITDA | 8.28 |
| EV / EBIT | 15.47 |
| EV / FCF | 14.49 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.57 |
| Quick Ratio | 1.17 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 2.99 |
| Debt / FCF | 5.29 |
| Interest Coverage | 3.38 |
Financial Efficiency
Return on equity (ROE) is 7.36% and return on invested capital (ROIC) is 4.36%.
| Return on Equity (ROE) | 7.36% |
| Return on Assets (ROA) | 1.92% |
| Return on Invested Capital (ROIC) | 4.36% |
| Return on Capital Employed (ROCE) | 4.75% |
| Weighted Average Cost of Capital (WACC) | 4.83% |
| Revenue Per Employee | 1.22B |
| Profits Per Employee | 43.44M |
| Employee Count | 224 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 3.86 |
Taxes
In the past 12 months, Theragen Etex has paid 5.31 billion in taxes.
| Income Tax | 5.31B |
| Effective Tax Rate | 32.95% |
Stock Price Statistics
The stock price has decreased by -14.93% in the last 52 weeks. The beta is 0.21, so Theragen Etex's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -14.93% |
| 50-Day Moving Average | 2,865.80 |
| 200-Day Moving Average | 2,842.40 |
| Relative Strength Index (RSI) | 31.77 |
| Average Volume (20 Days) | 159,794 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Theragen Etex had revenue of KRW 272.93 billion and earned 9.73 billion in profits. Earnings per share was 259.82.
| Revenue | 272.93B |
| Gross Profit | 141.21B |
| Operating Income | 7.66B |
| Pretax Income | 16.11B |
| Net Income | 9.73B |
| EBITDA | 14.17B |
| EBIT | 7.66B |
| Earnings Per Share (EPS) | 259.82 |
Balance Sheet
The company has 39.59 billion in cash and 42.44 billion in debt, with a net cash position of -2.85 billion or -77.77 per share.
| Cash & Cash Equivalents | 39.59B |
| Total Debt | 42.44B |
| Net Cash | -2.85B |
| Net Cash Per Share | -77.77 |
| Equity (Book Value) | 152.04B |
| Book Value Per Share | 3,595.62 |
| Working Capital | 52.74B |
Cash Flow
In the last 12 months, operating cash flow was 10.73 billion and capital expenditures -2.72 billion, giving a free cash flow of 8.02 billion.
| Operating Cash Flow | 10.73B |
| Capital Expenditures | -2.72B |
| Depreciation & Amortization | 6.48B |
| Net Borrowing | -8.29B |
| Free Cash Flow | 8.02B |
| FCF Per Share | 218.54 |
Margins
Gross margin is 51.74%, with operating and profit margins of 2.81% and 3.57%.
| Gross Margin | 51.74% |
| Operating Margin | 2.81% |
| Pretax Margin | 5.90% |
| Profit Margin | 3.57% |
| EBITDA Margin | 5.19% |
| EBIT Margin | 2.81% |
| FCF Margin | 2.94% |
Dividends & Yields
Theragen Etex does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 1.02% |
| Buyback Yield | -14.95% |
| Shareholder Yield | -14.95% |
| Earnings Yield | 10.46% |
| FCF Yield | 8.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Theragen Etex has an Altman Z-Score of 2.03 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.03 |
| Piotroski F-Score | 8 |